







an Open Access Journal by MDPI

# Advances in the Molecular Pathogenesis of T-cell Lymphoma

Guest Editor:

#### Dr. Richard Flavin

Department of Histopathology, St James's Hospital, Trinity College Dublin, Dublin 8, Ireland

Deadline for manuscript submissions:

31 December 2024

## **Message from the Guest Editor**

Dear Colleagues,

With the recent advent of high-throughput technologies, there have been many advances in our understanding of the molecular pathogenesis of T-cell lymphoma. The parallel classification of T-cell lymphoma has been further refined, and novel prognostic and theranostic biomarkers have been identified. The purpose of this Special Issue is to highlight recent advances in the molecular pathogenesis of T-cell lymphomas. Original research articles and comprehensive reviews are welcome.

Dr. Richard Flavin *Guest Editor* 













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**